Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PF-07304814 in hospitalized COVID-19 patients
NCT05780541Phase 3Terminated
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Sep 2021
- Primary completion
- Apr 2022
- Modality
- Prodrugs/Conditional Activator Small Molecules
- Countries
- 2
01
Overview
A Phase 3 trial of lufotrelvir in coronavirus disease 2019 (COVID-19), sponsored by National Institute of Allergy and Infectious Diseases. Started Sep 2021; status: terminated.
02
Drugs
lufotrelvir
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05780541.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05780541.